Map
Live
US Code
Officials
Committees
Legislation
Rankings
Nominations
Holds
Stocks
Open search page

Text Versions

Text as it was Introduced in House
April 28, 2025•21 pages
View
Congress.wiki Alpha
AboutHow Congress WorksSupport UsRoadmapPrivacy PolicyTerms of Service

This is not an official government website.

Copyright © 2026 PLEJ LC. All rights reserved.

AI Insights

Analyzed 2 of 2 sections

Summary

Creates a new tax subchapter for “economically distressed zones” (details of the subchapter were not provided) and makes those tax changes effective for taxable years beginning after December 31, 2024. It also broadens health law authorities to identify and prioritize “population health products” — drugs and therapeutics for people with non‑communicable (chronic) conditions who face worse outcomes during pandemics — expands what counts as a qualified countermeasure, directs HHS to accelerate R&D, manufacturing, distribution and stockpiling for those products, and requires a report to Congress within 90 days on needs and incentives.

Key Points

  • Creates a new tax subchapter for “economically distressed zones” with an effective date for tax years beginning after Dec 31, 2024.
  • Establishes and defines “population health products” — drugs for people with non‑communicable (chronic) conditions who are at higher risk during pandemics.
  • Expands the legal definition of qualified countermeasures to include population health products and related strategic activities (R&D, manufacturing, stockpiling, technologies).
  • Directs the HHS Secretary to prioritize R&D, coordinate across federal agencies, and accelerate delivery of approved products to vulnerable populations.
  • Requires HHS to report to Congress within 90 days of enactment on unmet needs and incentives to support development and distribution of these products.
  • The bill sets program priorities and reporting requirements but does not specify new appropriations in the provided text.
  • Impacts include greater federal focus on drugs for chronic-condition populations during public health emergencies and potential tax benefits or programs for designated distressed areas.
  • Implementation will involve HHS, NIH/FDA, manufacturers, and state/local partners to reach named vulnerable groups.

Categories & Tags

Agencies
Department of Health and Human Services (HHS) / Secretary
Centers for Medicare & Medicaid Services (Administrator of CMS)
Department of Defense (Secretary of Defense)
Department of Veterans Affairs (Secretary of Veterans Affairs)
Food and Drug Administration (Commissioner of Food and Drugs)
+2 more

Provisions

9 items

Adds a new subchapter at the end of Chapter 1 of the Internal Revenue Code of 1986 concerning Economically distressed zones.

amendment
Affects: Internal Revenue Code of 1986 (federal tax law)?

The amendments made by this section apply to taxable years beginning after December 31, 2024.

deadline
Effective: 2025-01-01

Amends the definition of “qualified countermeasure” in subparagraph (A) of section 319F–1(a)(2) of the Public Health Service Act to include drugs, biological products, or devices that the Secretary determines are priorities, including products to address underlying non‑communicable diseases when combined with pandemic influenza or an emerging infectious disease (two clause structure: (i) and (ii)).

amendment
Affects: Secretary of Health and Human Services; qualified countermeasures

Adds a new definition of “population health product” to subsection (a) of section 319L: a widely available drug to diagnose, mitigate, prevent, or treat harm from an underlying non‑communicable disease which, combined with pandemic influenza or an emerging infectious disease, may cause adverse health consequences or serious threat to one or more vulnerable American populations in an epidemic or pandemic.

definition
Affects: Population health product (as newly defined)

Adds a new definition of “vulnerable American populations” to subsection (a) of section 319L, listing children, pregnant women, older adults, minority populations, and other at‑risk individuals with relevant characteristics to consider during research and development of countermeasures and products.

definition
Affects: Vulnerable American populations (as newly defined)
Subjects
Taxation
economically distressed zones
tax code amendments
public health
pandemic preparedness
medical countermeasures
+4 more
Affected Groups
Individuals with chronic health conditions or disabilities
Drug manufacturers and applicants
Department of Health and Human Services personnel
Small businesses (in economically distressed areas)
+3 more

Impact Analysis

Who is affected and how:

  • People with chronic/non‑communicable diseases (direct effect): The bill directs federal attention to drugs and therapies that reduce pandemic‑related harms for these individuals. That could speed development, approval support, manufacturing scale‑up, prioritization for distribution, and stockpiling for these groups.

  • Vulnerable American populations (direct effect): The bill defines and prioritizes “vulnerable” groups for access to approved population health products; those groups may receive earlier access during emergencies and be the focus of distribution strategies.

  • Drug developers and manufacturers (direct effect): Federal prioritization, expanded countermeasure status, and potential incentives will increase demand signals and regulatory attention for companies that develop population health products. This could change R&D and production investment decisions.

  • Department of Health and Human Services and other federal agencies (direct effect): HHS must establish priorities, coordinate across agencies, and report to Congress. This creates new administrative duties and potential reallocation of existing program resources.

  • Residents and businesses in designated economically distressed zones (direct/moderate effect): The new tax subchapter is intended to change tax treatment or incentives for economically distressed areas; affected taxpayers, businesses, and local governments may receive new tax benefits or eligibility, depending on the subchapter’s content (not provided).

  • Public health and supply chain systems (indirect effect): Expanded emphasis on manufacturing and stockpiling could accelerate investments in domestic production capacity, supply chain resilience, and logistics for getting products to prioritized groups.

Risks and unknowns:

  • Funding: The excerpt does not specify new appropriations, so outcomes depend on available HHS resources and whether Congress provides funding to implement priorities, support manufacturing, or create financial incentives.

  • Definitions and scope: How broadly “population health products” and “vulnerable American populations” are defined will strongly affect which conditions and populations are prioritized.

  • Regulatory and timeline uncertainty: Practical impact depends on FDA regulatory pathways, contractor capacity, and the speed of interagency coordination.

Overall, the legislation directs federal focus toward safeguarding people with chronic diseases in pandemics and introduces tax changes targeting economically distressed areas; the magnitude of effects will depend on implementing guidance, funding decisions, and the final tax text.

Related Legislation

No Related Legislation

Amendments

No Amendments

House Votes

Pending Committee
April 28, 2025 (8 months ago)

Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Senate Votes

Vote Data Not Available

Presidential Signature

Signature Data Not Available
United StatesHouse Bill 3042HR 3042

MMEDS Act of 2025

21 pages
  1. house
  2. senate
  3. president

Last progress April 28, 2025 (8 months ago)

Introduced on April 28, 2025 by Nicole Malliotakis

Sponsors (11)